Related Experiment Video
Updated: Aug 2, 2026
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules
G P Adams1, R Schier, A M McCall
1Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Abstract:
Antitumor monoclonal antibodies must bind to tumor antigens with high affinity to achieve durable tumor retention. This has spurred efforts to generate high affinity antibodies for use in cancer therapy. However, it has been hypothesized that very high affinity interactions between antibodies and tumor antigens may impair efficient tumor penetration of the monoclonal antibodies and thus diminish effective in vivo targeting (K. Fujimori et al., J. Nucl. Med., 31: 1191-1198, 1990). Here we show that intrinsic affinity properties regulate the quantitative delivery of antitumor single-chain Fv (scFv) molecules to solid tumors and the penetration of scFv from the vasculature into tumor masses. In biodistribution studies examining a series of radioiodinated scFv mutants with affinities ranging from 10(-7)-10(-11) M, quantitative tumor retention did not significantly increase with enhancements in affinity beyond 10(-9) M. Similar distribution patterns were observed when the scFv were evaluated in the absence of renal clearance in anephric mice, indicating that the rapid renal clearance of the scFv was not responsible for these observations. IHC and IF evaluations of tumor sections after the i.v. administration of scFv affinity mutants revealed that the lowest affinity molecule exhibited diffuse tumor staining whereas the highest affinity scFv was primarily retained in the perivascular regions of the tumor. These results indicate that antibody-based molecules with extremely high affinity have impaired tumor penetration properties that must be considered in the design of antibody-based cancer therapies.
Insights
High-affinity antibodies for cancer therapy may hinder tumor penetration. This study shows that extremely high affinity impairs single-chain variable fragment (scFv) delivery into solid tumors, impacting cancer treatment design.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- High-affinity monoclonal antibodies (mAbs) are crucial for durable tumor retention in cancer therapy.
- The hypothesis exists that excessive antibody-antigen affinity may impede mAb penetration into tumors, reducing in vivo targeting efficacy.
Purpose of the Study:
- To investigate how intrinsic affinity properties of single-chain Fv (scFv) molecules influence their delivery and penetration into solid tumors.
- To determine the optimal affinity range for effective tumor targeting by scFv-based therapeutics.
Main Methods:
- Biodistribution studies using radioiodinated scFv mutants with varying affinities (10^-7 to 10^-11 M).
- Evaluation of scFv distribution in both normal and anephric mice to exclude renal clearance effects.
- Immunohistochemistry (IHC) and immunofluorescence (IF) analyses of tumor sections to assess scFv penetration and localization.
Main Results:
- Quantitative tumor retention did not significantly increase for affinities higher than 10^-9 M.
- Similar distribution patterns were observed in normal and anephric mice, ruling out renal clearance as the primary factor.
- Lowest affinity scFv showed diffuse tumor staining, while highest affinity scFv localized primarily in perivascular regions.
Conclusions:
- Extremely high affinity of antibody-based molecules can impair tumor penetration.
- Antibody affinity is a critical factor that must be considered in the design of antibody-based cancer therapies for optimal delivery and efficacy.
